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Abstract
Background: Individuals with liver disease, and especially those with Hepatitis B or C, are at an increased risk of developing
hepatocellular carcinoma (HCC) which is the third most common cause of cancer-related death worldwide. Inadequate
screening tests largely account for presentation of advanced tumours and high mortality rates. Early detection of HCC
amongst high-risk groups is paramount in improving prognosis. This research aimed to further characterise the previously
described humoral immune response raised to tumour-associated antigens (TAAs) in the serum of patients with HCC.
Methods: Serum from 96 patients with confirmed HCC, 96 healthy controls matched for age and sex, 78 patients with
confirmed liver cirrhosis and 91 patients with confirmed chronic liver disease were analysed for the presence of IgG
autoantibodies raised to 41 recombinant TAAs/antigen fragments by ELISA.
Results: Varying autoantibody specificities (97–100%) and sensitivities (0–10%) were observed to individual TAAs. A 21-
antigen panel achieved a specificity of 92% and sensitivity of 45% for the detection of HCC. This same panel identified 21%
of 169 high-risk controls as having elevated autoantibody levels. A reproducible panel of 10 antigens achieved a specificity
of 91% and sensitivity of 41% in HCC. 15% of 152 high-risk controls gave positive results with this panel.
Conclusions: This minimally invasive blood test has the potential to offer advantages over currently available tools for the
identification of HCC amongst pre-disposed patients. Results are comparable to current gold standards in HCC
(Ultrasonography) and to similar tests in other cancers (EarlyCDT-Lung).
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the third most common cause of cancer-related death
worldwide. Inadequate screening tests largely account for presen-
tation of advanced tumours, poor prognosis and high mortality
rates [1]. Between 1975 and 2009 in Great Britain, the age
standardised incidence rates of liver cancer increased from 1.4 to
4.7 per 100,000 populations, reflecting what has become a global
rise in HCC incidence. Approximately 3,960 new cases of liver
cancer were diagnosed in the UK in 2009, leading to 3,800 liver
cancer deaths in 2010 [2].
Worldwide, HCC incidence rates vary greatly and reflect the
geographic distribution of risk factors (infection with hepatitis B or
C viruses accounting for 85% of all HCC cases). HCC is most
prevalent in the developing world; 82% of diagnosed HCC and
HCC-related deaths occur in countries located in Southeast Asia
and sub-Saharan Africa [3]. Despite its relatively lower preva-
lence, countries such as the USA and Japan are now also falling
victim to the HCC burden [4].
For many years, surveillance of patients with pre-disposing liver
conditions has comprised bi-annual serological screening tests
(alpha-fetoprotein (AFP)) and/or imaging examinations (ultra-
sound), yet sensitivity for the detection of early stage HCC is
universally considered sub-optimal. Measurement of AFP-L3 has
also been investigated however a recent meta-analysis comparing
AFP with AFP-L3 did not infer any significant improvement in
cancer detection over AFP alone [5].
Recent investigations into the effect of applying AFP testing in
addition to ultrasonography for surveillance of early HCC found
that the marginal increase in sensitivity from 63% to 69% was not
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statistically significant. The use of AFP in surveillance of HCC is
therefore not recommended by the most recent clinical practice
guidelines [6]. Early detection of HCC amongst high-risk groups is
paramount in improving prognosis, through enabling curative
treatment options to be administered prior to manifestation of
advanced and metastatic disease.
The presence of an elicited humoral immune response, in the
form of IgG autoantibodies raised to Tumour-Associated Antigens
(TAAs) in the sera of cancer patients, is well evidenced in the
literature. Autoantibodies can be produced in response to
mutated, over- or aberrantly expressed TAAs and may provide
an in vivo amplification in patient sera of early carcinogenesis [7].
The presence of autoantibodies to TAAs has been described in
several tumour types including breast [7-9)] ovarian [10], gastric
[11] lung [12-15], colorectal [16], pancreatic [17] and oesopha-
geal [18], and may be present years before clinical manifestation of
the disease [19–23].
Techniques such as SEREX [24] T7 phage display [25], two-
dimensional gel electrophoresis (2DE) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) [26], amongst others,
have been successfully employed for the detection of AAbs raised
to TAAs in HCC and in patients with pre-disposing liver disease
[27,28]. However, previous studies have generally been performed
using relatively small numbers of TAAs and with inappropriate
control groups.
The aim of this study was to compare the performance of 41
TAAs/antigenic fragments in detecting a specific autoantibody
response in the sera of patients with HCC using a high-throughput
Enzyme Linked Immunosorbant Assay (ELISA). In contrast to
many other published studies [27,28], this study used control sera
from age- and gender-matched individuals in order to show a true
cancer versus ‘normal’ differentiation.
Materials, Patients and Methods
This research was approved by the authors’ institutional review
boards and samples collected following approval by the University
of Nottingham Research Ethics Committee (REC), Derbyshire
REC and by the University of Munich Ethics Committee at the
Medical Faculty of the Ludwig-Maximilians University, Munich).
All samples were collected with written, informed consent at each
of the respective collection centres. Sera were stored at 270uC
prior to use.
Selection of TAAs for Analysis
Using the literature as a source, antigens were selected for use in
this study based on i) their association with HCC or liver disease
and a previously uncharacterised autoantibody profile e.g. AFP,
Gankyrin and GPC-3 or ii) proteins with a demonstrable
immunogenicity in HCC [27,28]; IMP1, p62, Koc, p53, c-myc,
Cyclin B1, Survivin and p16, or other solid tumours, e.g. lung
[21,29]; SOX-2, CAGE, NY-ESO-1, GBU4-5, MAGE A-4, and
HuD. Full-length recombinant proteins were produced where
possible. In cases where PCR failed to amplify from template
cDNA, primers were designed to allow the amplification of
antigenic fragments of interest, e.g. the specific thioesterase domain
of FASN was chosen for selective amplification due to its region-
specific association with cancer [30].
Serum Samples and Patient Details
HCC. 57 HCC serum samples were collected (within 6
months of HCC diagnosis) at the Queen’s Medical Centre,
Nottingham, UK and 50 HCC serum samples were collected from
the University Hospital Munich, Germany. A further 9 HCC
serum samples were purchased from the Clinical Research Centre
of Cape Cod. HCC diagnosis was confirmed either by BCLC
staging classification [6] or as per Barcelona EASL Conference
2000 criteria [31].
Controls. 169 samples from patients enrolled in the Trent
study of patients infected with hepatitis C with either cirrhosis
(n = 78) or chronic liver disease (n = 91) were used as high-risk
controls. Healthy control samples were age- and gender- matched
from a cohort of over 3,500 sera collected from healthy individuals
in the East Midlands Area, with no evidence of liver disease.
Tumour-Associated Antigen (TAA) Production
41 proteins, as well as a control antigen, BirA (which encodes a
14 kDa BirA recognition sequence) were produced as described
below (for further details see supporting information, Table S1).
Where possible, cDNAs were sourced from sequence verified
IMAGE clones (Source Bioscience). Alternatively, cDNA was
synthesised from Huh7 cell line mRNA according to the
manufacturer’s instructions (QuantiTect Reverse Transcription
Kit, QIAGEN). Full length antigens or antigenic fragments were
either i) sub-cloned into pET21b-BirArs as previously described
[32,33] or ii) sub-cloned into a C-terminally tagged Ligation
Independent Cloning (C-LIC) vector containing BirArs [34].
TAA-containing vectors were transformed into E.coli and
cultured as either i) 30 ml cultures in deep well plates (n = 26) ii)
as 200 ml shake-flask cultures (n = 8) or iii) as 5–15 L cultures
(n = 8). Proteins were purified as previously described using IMAC
His-Select filter plates (Sigma) [34] (n = 26) or His-trap FF-crude
columns (GE) [25,26] (n = 16). Fifteen promising antigens were
also remade in 200 ml shake-flask cultures and purified using His-
trap FF-crude columns, for analysis of antigen reproducibility.
Autoantibody Detection
Autoantibodies were detected by ELISA according to previously
described methods [34]. The BirA control was included to allow
subtraction of any assay signal due to nonspecific binding.
In brief 41 TAAs/antigenic fragments (see supporting informa-
tion), and 2 assay controls (BirA and buffer only) were adsorbed to
ELISA plates in duplicate and at 2 concentrations of antigen
(100 nM and 50 nM). These proteins were then incubated with
serum samples from cancer, high-risk and healthy control cohorts
(Table 1) diluted 1 in 110 in blocking buffer. The presence of an
IgG response to the antigens was detected with horseradish
peroxidase-conjugated rabbit anti-human IgG (Dako) and
3,39,5,59-tetramethylbenzidine, as previously described [29]. All
assays were conducted on a semi-automated robotic system and
cancer, high-risk and healthy control samples were interspersed.
Incubations with anti-His monoclonal antibody (AbCam) and,
where available antigen-specific monoclonal antibodies (Sigma,
AbCam, Santa-Cruz), were carried out to validate antigen plate
coating. SDS-PAGE analysis of TAA plate-coating solutions was
also carried out to verify plate layouts and protein dilutions.
Autoantibody Data Analysis
Raw OD data was imported from the Tecan Infinite plate
reader into Microsoft Excel for analysis using purpose-designed
spreadsheets. The mean OD reading of the BirA control was
subtracted from the mean OD readings of antigen-coated wells.
Intra-assay reproducibility was determined by calculating the
Coefficient of Variation (CV) for each dilution.
Optimised antigen cut-offs (for maximal cancer: normal
differentiation), as well as a standard cut-off that corresponded
to a value greater than the mean plus 4 Standard Deviations (SD)
of the healthy control cohort, were applied to each antigen.
Autoantibodies in Hepatocellular Carcinoma
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Statistical analysis was performed using Microsoft Excel, IBM
SPSS Statistics 21 or GraphPad Prism 6. The 2-sample
Kolmogorov-Smirnov test was used for the analysis of two
separate distributions and the 1-sample Kolmogorov-Smirnov
‘goodness of fit’ test employed to analyse the normality of the data
[35].
Significance analysis was subsequently performed using the
Mann-Whitney U and Pearson Chi-Square tests on non-
parametric data. Overall data sensitivity and specificity were
estimated to determine the usefulness of autoantibody detection, in
terms of diagnostic potential.
Results
Sample cohort demographics and details of the underlying
disease aetiology are included in Table 1. No difference was
observed in autoantibody signal between UK and German HCC
sample cohorts.
Analysis of Individual Antigens
Antigens were initially grouped according to their K-S scores
(data not shown), analysis of dot blots and their ability to
differentiate between cancer and healthy control (‘normal’)
cohorts. Details of the antigens analysed, and individual sensitiv-
ities for 21 of the antigens are shown in table 2 (study 1). The other
20 antigens demonstrated no cancer: normal differentiation and
are shown as a group of rejected antigens. Examples of dot blots
for some of the antigens are exemplified in Fig. 1. Some TAAs
such as NY-ESO-1, p53, HRAS1 and RalA showed good
differentiation between HCC and healthy control sera, as shown
by the circled cloud of positive samples in the HCC cohort. Other
TAAs such as FASN, AFP, Gankyrin and Survivin showed much
less differentiation whilst KOC, p62, GPC-3 and Alpha-enolase
showed extremely poor differentiating ability between cohorts.
Antigens were also grouped according to their ability to
differentiate between cancer and high-risk sample cohorts. Dot
blots for some of the antigens are exemplified in Fig. 2; some
antigens such as NY-ESO-1 maintained the promising differen-
tiation shown previously between cancer and healthy control
cohorts. Other TAAs such as p53 and Gankyrin showed reduced
cohort differentiation and Cyclin B1 showed no cohort differen-
tiation.
Antigen Panel Selection
Further analysis of the 41 antigens (Table 2), using a
standardised cut-off for each antigen of an OD value equal to or
greater than the mean plus 4SD of the healthy control cohort,
identified 5 discrete TAA panels of between 1 and 21 antigens
(Table 3). Testing was based on 96 HCC and 96 matched healthy
control samples. The percentage of high-risk samples with elevated
autoantibody levels was also investigated for each antigen panel.
Sensitivity for cancer detection increased from 7% to 41% with a
12 antigen panel, and to 45% for a 21 antigen panel, whilst
specificity was maintained at .90%. In all cases more high-risk
individuals than normal matched controls were identified.
TAA panels and association with HCC stage and
aetiology
45% of HCC patients tested were identified as positive to one or
more TAAs. Sub-analysis of autoantibody positivity rates in
tumours of different aetiologies was not possible, owing to lack of
aetiological data relating to many of the HCC samples. Similarly,
we were not able to discern whether reactivity with any particular
TAA was related to underlying HCC aetiology.
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Clinical information on tumour stage was limited. 16 patients
were known to have early stage disease (BCLC Stage A) at the
time of venous puncture. Of these, 11 were initially identified as
positive (positivity to 1 or more TAAs from 41 TAAs tested), of
which 8 were autoantibody positive in the 21 TAA panel.
Sera prior to HCC diagnosis were available from 11 patients.
Seven of these had raised autoantibody levels to at least 1 TAA
(from a panel of 12) up to 5 years before the cancer had been
clinically diagnosed.
Normality and Significance testing
Normality testing classified all data as non-parametric (data not
shown). Mann-Whitney U significance data confirmed that l-myc-
2 (p = 0.03) was the only antigen to significantly differentiate
between cancer and healthy serum cohorts (HCC . healthy
controls), and AFP-C (p = 0.04), NY-ESO-1 (p= 0.04) and DKK1
(p=,0.01) were the only antigens to significantly differentiate
between cancer and high-risk serum cohorts (HCC . high-risk
controls). The 21 TAA panel achieved significant differentiation
between all sample cohorts (p =,0.01).
Panel Reproducibility
The 21 best performing TAAs were selected for closer analysis.
Five of these had already been produced in large scale and 16,
initially derived from small-scale production, were re-purified on a
larger scale. Following larger scale purification varying autoanti-
body specificities (96%–100%) and sensitivities (0%–8%) were
again detected to each of 21 TAAs in the sera of patients with
Figure 1. Dot plots of the mean OD autoantibody signal received from each serum sample against 9 TAAs. NY-ESO-1, p53, H-RAS-1 and
RalA (A), FASN, AFP, Gankyrin and Survivin (B) and KOC, p62, GPC-3 and Alpha-enolase (C). Data for each antigen is shown as cancer then matched
control. Error bars signify the mean with 95% confidence interval. Circled data points identify positive HCC responses.
doi:10.1371/journal.pone.0103867.g001
Table 2. Comparison of individual antigen specificities and sensitivities.
TAA STUDY 1 STUDY 2
Specificity (%) Sensitivity (%)
High Risk
Positivity Specificity (%) Sensitivity (%)
High Risk
Positivity
(%) n=169) (%) (n=152)
AFP 97 8 3 96 8 4
Cyclin B1 97 10 5 97 8 5
Gankyrin 99 5 4 99 5 2
p53 100 7 4 98 7 3
NY-ESO-1 100 5 2 100 5 1
RalA 99 10 4 99 4 3
CK8 100 3 1 100 5 3
GRP78 98 6 3 98 4 4
HDGF 98 6 3 97 6 1
DKK1 99 0 0 99 3 0
H-RAS-1 100 7 3 100 1 1
p16 99 6 4 99 1 2
WT1 (n terminal) 99 6 2 99 1 1
HCC1 100 4 1 100 0 0
Sui1 98 8 3 98 4 4
l-myc2 98 4 2 98 3 4
GPC-3 98 10 3 98 0 1
Beta-Catenin2 97 5 1 97 1 6
Beta-HCG 99 8 0 98 2 2
Calreticulin 99 3 1 99 1 0
FASN 100 2 0 100 2 1
21 Antigen Panel
(above)
92 45 21 88 43 n/a
Rejected Antigen Panel
(n = 20)
80 23 n/a n/a n/a n/a
Data shown for 96 cancers (% sensitivity), 96 matched normal sera (% specificity) and at risk sera (% positivity). Study 1: Data from initial screen of 41 antigens. Study 2:
Data from the 21 lead antigens. Individual cut-offs for each antigen were applied to maximise cancer: normal differentiation.
TAA – tumor-associated antigens. n/a – not assessed.
Rejected antigens = Vitronectin; Survivin; KOC; p62; a-enolase; c-myc; GBU4-5, b-Catenin 1; CAGE; HuD; H-RAS-2; PRDX6; IMP1; K-RAS; MAGE-A4; MAGE-C2; SOX2; SSX1;
VEGF-C; WT1-c-terminal.
doi:10.1371/journal.pone.0103867.t002
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HCC and patients with liver disease compared to serum from
healthy volunteers, confirming the initial results from this study
(table 2, study 2). Following optimisation of the cut off for the
detection of HCC samples (when compared to matched healthy
controls), the 21 antigens were able to identify 43% of the HCC
samples with a slightly reduced specificity of 88%.
Figure 2. Dot plots of the mean OD autoantibody signal received from each serum sample from all four cohorts, against 4 TAAs.
(NY-ESO-1 (A), p53 (B), Gankyrin (C) and Cyclin-B1 (D). Error bars signify the mean with 95% confidence interval. Circled data points identify positive
HCC responses. Horizontal lines above data sets indicate the OD value of mean plus 2SD of the normal control cohort.
doi:10.1371/journal.pone.0103867.g002
Autoantibodies in Hepatocellular Carcinoma
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To increase the utility of a panel of antigens, and remove
redundant antigens (eg those that were found to be non-
reproducible following high volume purification, or those that
did not identify unique cancers) sub-panels were again investigat-
ed. Seven of the antigens were found to still differentiate between
cancer, normal and high risk sera (AFP, Cyclin B1, Gankyrin, p53,
NY-ESO-1, RalA, CK8) whilst other promising antigens H-RAS-
1, p16, WT1, HCC1 and Sui1 were no longer found to be
additive.
A reproducible sub-panel consisting of these 7 TAAs plus 3
others (GRP78, HDGF and DKK1) gave a specificity and
sensitivity for identification of HCC of 91%/41% when compared
to matched healthy control sera. 15% of ‘at risk’ individuals were
also found to give positive results with this panel.
Discussion
Serum autoantibody detection has been proposed as an effective
aid to the early identification of HCC in patients considered at
increased risk of cancer development [27,28,36]. A reproducible
panel of 10 TAAs, was found to carry a diagnostic specificity of
91% and sensitivity of 41%. Such a specificity and sensitivity is a
comparable diagnostic accuracy to that reported as being of
clinical utility in lung cancer [14,29] and with further optimisation,
has the potential to improve on the diagnostic accuracy for early
stage disease, offered by gold standards in HCC (AFP/US
imaging) [6].
This study improves on previous studies reporting on autoan-
tibodies in HCC, as there are a number of limitations in many of
the published studies including numbers of TAAs tested per study -
e.g. Zhang et al and Chen et al. used only 10 TAAs [27,28]; the
inappropriate use of un-matched ‘normal’ control groups, and low
numbers of high-risk samples potentially introducing various
biases in age, gender and socioeconomic class into the control
cohort [27,28]. In addition few studies report whether or not their
findings were reproducible when run on a different day with a
second batch of the same proteins. This study aimed to address
these limitations by firstly investigating the autoantibody response
to an initial panel of 41 TAAs/antigenic fragments; secondly,
through screening a more robust sample set; 96 HCC, 96 age- and
gender-matched healthy control sera, 91 chronic hepatitis and 71
liver cirrhosis serum samples (where possible, healthy control sera
were also matched to HCC samples according to smoking history)
and thirdly we produced different batches of the same protein and
re-ran the samples to show reproducibility of results.
The 21 best performing TAAs selected for closer analysis
included TAAs previously identified as promising leads in HCC
such as IMP-1, KOC, p53 and c-myc [27], Sui1 and RalA [28],
Calreticulin [37], and HCC1 [38] together with novel proteins
such as Gankyrin and FASN, and well-known liver biomarkers
such as AFP, GPC-3 and GRP78. Testing a large number of
TAAs i) enabled the identification of several new leads including
HRAS1, Gankyrin, and CK8, ii) confirmed some leads previously
published including RalA, Sui1 and p53 [28] and in other cases,
iii) contradicted previous reports on promising antigen perfor-
mance, such as KOC, p62 and c-myc [27]. Reasons for
discrepancies between published studies will be multi-factorial,
including sample size, and selection of more or less appropriate
control groups as well as antigen production methodologies.
Differences in sample set demographics may also be relevant,
reflecting differing HCC aetiologies in different studies.
The importance of optimal antigen production was highlighted
in this study given that not all antigens that initially displayed a
good differentiating ability between cancer and healthy controls,
maintained their ability to do so on re-purification. These results
demonstrate the need for optimal antigen production and
validation before commercialisation of such tests. Alternative
methods for production of these antigens (in terms of expression
and purification) may, in future, enable them to be included in a
test for HCC.
The promise held by panel autoantibody detection has
previously been evidenced in HCC as well as other cancers such
as lung [12–14,29]. Our results confirm that no single antigen
alone can identify large numbers of positive samples. We have
shown that increasing the TAA panel to include 21 as opposed to
4 antigens resulted in a doubling of sensitivity from 23% to 45%
whilst specificity was only reduced from 96% to 92%. We had
access to a well characterised cohort of sera from healthy
volunteers and at risk individuals, thereby enabling crucial age-
and gender- matching of HCC samples, and analysis of
autoantibody patterns in important at-risk groups. We were also
able to use a technically and clinically validated assay platform
technology thereby ensuring autoantibody assays were conducted
in a highly reproducible manner [32,33]. We note that Zhang et
al, and Chen et al. reported sensitivities of 67% to a panel of 10
antigens [27,28], however, their failure to use appropriately age-
and sex-matched controls leaves a significant clinically relevant
question on their assay performance unanswered.
One limitation of our study is the lack of aetiological
information for many of our HCC sera, which precludes analysis
of whether TAA panels could be tailored to detect specific
Table 3. Comparisons of specificity and sensitivity in 5 different TAA panels.
Number of TAAs in panel Specificity/Sensitivity (%) High-risk Positivity (%) (n =169)
1 100/7 3
4 96/23 9
8 96/30 14
12 92/41 18
21 92/45 21
Panel composition was as follows:
1 = H-RAS-1;
4 = H-RAS-1 + p16 + Gankyrin + NY-ESO-1;
8 = Panel 4 + Sui1, p53, RalA, CyclinB1;
12 = Panel 8 + HCC1, WT1-n-term, CK8, AFP;
21 = Panel 12 + b-Catenin2, b-HCG, HDGF, Calreticulin, GRP78, FASN, GPC-3, DKK1, l-myc-2.
doi:10.1371/journal.pone.0103867.t003
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aetiological sub-types of HCC. However, even if the data for all 96
cases was available, the numbers would have been too small for
each of the main aetiological causes (ie HBV, HCV and alcohol) to
infer panel preferences. This however remains an attractive area
for further research.
Of particular interest is the evidence that autoantibody
responses can be detected in patients at an early stage of disease
(BCLC stage A [6]) and in some cases, up to 5 years prior to
clinical diagnosis. This is in keeping with previous reports where
autoantibodies to TAAs have been reported between 0.5–4 years
before symptomatic presentation in lung, breast and colon cancer
[20–23] and up to 5 years before detection of lung cancer in a CT
screening study [19].
The reproducible panel of 10 TAAs, included novel HCC
antigens such as Gankyrin and CK8, achieved the specificity of
91% and sensitivity of 41%, even upon partial scale-up of antigen
and despite the fact that 3 of the originally identified antigens were
no longer found to be additive to the panel, illustrating that
optimisation of protein production prior to commercial launch of a
test, is paramount.
Autoantibodies to 10 antigens were also evident at raised levels
in 15% of at risk individuals. One possible reason for the positivity
amongst the high risk group is the presence of a developing but as
yet undiagnosed HCC. If longitudinal studies are carried out in
the future, and this group do indeed go on to develop HCC and
the remaining do not, it is possible to speculate that the test could
be detecting an immune response to a few early HCC cells present
in the liver of such patients. Clearly future studies with appropriate
follow-up will be needed to address this hypothesis, however this
may prove to be a significant group to follow, as the five-year
cumulative risk for HCC in patients with HCV-related cirrhosis
can be as high as 17% in Europe and the US, and 30% in Japan
[39].
A simple blood test, such as described here, would, once
optimised and validated, have the potential to offer an aid to the
clinician in assessing individuals at increased risk of developing the
disease. The ultimate aim of which would be the reduction of lives
lost to this malignancy through its detection at an early stage.
Supporting Information
Table S1 TAA Production. (A = 30 ml culture volumes and
HIS-Select filter plate purification; B and C = 200 ml and .5 L
culture volumes respectively with HIS-Trap FF-crude Fast Protein
Liquid Chromatography purification). * Denotes molecular weight
including BirA tag.
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